Consensus Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:50:00 15/01/2026 GMT			5-day change	1st Jan Change
66.68 ^USD	+1.18%		+2.56%	+0.41%

01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
01-12	Arrowhead Pharmaceuticals issues $700 million of 0.00% convertible notes due 2032 - SEC filing	RE

Evolution of the Average Target: Arrowhead Pharmaceuticals, Inc.

Evolution of the Target Price: Arrowhead Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Arrowhead Pharmaceuticals, Inc.

e152a73f1038e.bCJp4uneI2_rOi0rnbvHSs3RjL91vw7M7cUb5w8ybmU.G3hahtiqFSezdnpl_oPwIru2w_oF0Wn0rqd_1WNaHFIjVFqzgrxXONNwXg~c682567b0c0bfc27cf5c0868657f713b

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

01-07	Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating	MT
12-11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
11-19	RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
11-12	Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $45 From $29, Keeps Equalweight Rating	MT
22/10/25	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $61 From $38, Keeps Buy Rating	MT
08/10/25	RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk	MT
08/08/25	RBC Trims Price Target on Arrowhead Pharmaceuticals to $38 From $40, Keeps Outperform, Speculative Risk	MT
14/05/25	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating	MT
13/05/25	RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating	MT
14/02/25	B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating	MT
12/12/24	B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating	MT
03/12/24	HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	MT
27/11/24	Analyst recommendations: Nvidia, Workday, Doordash, Nutanix, T-Mobile...
22/08/24	Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...
09/08/24	Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...
23/07/24	Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...
05/07/24	HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	MT
10/05/24	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	MT
08/02/24	B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	MT
07/02/24	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	MT
04/12/23	BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target	MT
04/12/23	B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating	MT
30/11/23	Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating	MT
21/07/23	TD Cowen Starts Arrowhead Pharmaceuticals at Outperform	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARROWHEAD PHARMACEUTICALS, INC.					+18.65%
	ARGENX SE					+19.31%
	WUXI APPTEC CO., LTD.					+24.15%
	INSMED INCORPORATED					+32.01%
	BIONTECH SE					+26%
	WUXI BIOLOGICS (CAYMAN) INC.					+1.29%
	GENMAB A/S					-4.28%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+14.23%
	AKESO, INC.					+39.7%
	SUMMIT THERAPEUTICS INC.					+84.86%
	Average					+25.59%
	Weighted average by Cap.					+23.55%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

65.91USD

Average target price

78.20USD

Spread / Average Target

+18.65%

High Price Target

110.00USD

Spread / Highest target

+66.89%

Low Price Target

35.00USD

Spread / Lowest Target

-46.90%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Chardan Research
RBC Capital Markets
Morgan Stanley
B. Riley
UBS
HC Wainwright
BofA Securities
TD Cowen
Piper Sandler
SVB Securities LLC
Goldman Sachs
Bernstein
Baird
Jefferies & Co.
SVB Leerink
Chardan